| human | Q5 |
| P496 | ORCID iD | 0000-0002-9560-5576 |
| P3829 | Publons author ID | 2839412 |
| P1053 | ResearcherID | D-1083-2010 |
| P1153 | Scopus author ID | 6603858530 |
| P106 | occupation | researcher | Q1650915 |
| Q45880973 | A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful? |
| Q34129460 | A clinical pharmacokinetic study of tacrolimus and sirolimus combination immunosuppression comparing simultaneous to separated administration |
| Q36667898 | Acute liver failure induced by green tea extracts: case report and review of the literature. |
| Q40082665 | Blue-Print for Elimination of Hepatitis C Viral Infection: One Step Closer |
| Q26849591 | Burden of disease and cost of chronic hepatitis C infection in Canada |
| Q42939153 | Canada needs viral hepatitis action plan |
| Q80188046 | Canadian mortality rates for liver disease: taking a closer look at ICD coding |
| Q80162446 | Chylous ascites secondary to pancreatitis: management of an uncommon entity using parenteral nutrition and octreotide |
| Q42977629 | Clinical trial: exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alpha-2a plus ribavirin |
| Q83984213 | Clostridium difficile on the transplantation radar |
| Q82985525 | Colon cancer screening |
| Q42999544 | Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis |
| Q37134227 | Complementary and alternative medicine use by patients chronically infected with hepatitis C virus |
| Q34977603 | Coping strategies used by patients infected with hepatitis C virus who are facing medication costs. |
| Q60998200 | Cost of Liver Transplantation Using Tacrolimus |
| Q72780500 | Detection of Crohn's ileitis by endovaginal ultrasonography |
| Q42700149 | Diabetes mellitis: risk factor for advanced liver disease. |
| Q37045797 | Early invasive Listeria monocytogenes infection after orthotopic liver transplantation: case report and review of the literature. |
| Q44463528 | Early steroid withdrawal after liver transplantation: the Canadian tacrolimus versus microemulsion cyclosporin A trial: 1-year follow-up |
| Q42982132 | Effect of interferon-alpha, ribavirin, pentoxifylline, and interleukin-18 antibody on hepatitis C sera-stimulated hepatic stellate cell proliferation |
| Q27486399 | Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals |
| Q60301070 | Epidemiology and liver transplantation burden of primary biliary cholangitis: a retrospective cohort study |
| Q63916021 | Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), mycophenolate mofetil, and a delayed, low-dose tacrolimus regimen vs. a standard-dose tacrolimus and mycophenolate mofetil regimen: A multicenter randomized c |
| Q37396610 | Evidence-based approach to cholangiocarcinoma: a systematic review of the current literature. |
| Q27485351 | Exploring differences in response to treatment with peginterferon alpha 2a (40kD) and ribavirin in chronic hepatitis C between genotypes 2 and 3 |
| Q80186024 | Finally...real utility scores for hepatitis C patients! |
| Q37497860 | Future directions for investigation of fatigue in chronic hepatitis C viral infection |
| Q28943317 | Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis |
| Q38203033 | Historical epidemiology of hepatitis C virus (HCV) in selected countries. |
| Q42995306 | Identifying HCV genotype 1 patients at risk of relapse |
| Q34351600 | Immunoglobulin-G subclass antidonor reactivity in transplant recipients. |
| Q43213528 | Improving access to transient elastography in Canada will need more than evidence-based guidelines and technical health assessment. |
| Q27488232 | Induction versus noninduction antiviral therapy for chronic hepatitis C virus in patients with congenital coagulation disorders: a Canadian multicentre trial |
| Q43037748 | Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? |
| Q73308069 | Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B |
| Q36291810 | Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. |
| Q51466759 | Metabolic syndrome in liver transplant recipients: prevalence and association with major vascular events. |
| Q43710492 | Orthotopic liver transplantation using low-dose tacrolimus and sirolimus |
| Q35769129 | Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. |
| Q51935474 | Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. |
| Q24633806 | Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants |
| Q41623139 | Prostaglandins in liver failure and transplantation: regeneration, immunomodulation, and cytoprotection. Prostaglandins in Liver Transplantation Research Group. |
| Q36761430 | Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies |
| Q36655931 | Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop |
| Q33916743 | Rescue therapy using a rifabutin-based regimen is effective for cure of Helicobacter pylori infection. |
| Q36166366 | Review article: the changing epidemiology of hepatocellular carcinoma in Canada |
| Q46033909 | Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. |
| Q45342066 | Simultaneous liver kidney transplantation: a medical decision analysis |
| Q60998185 | Sirolimus-tacrolimus combination immunosuppression |
| Q40764902 | Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience |
| Q55539734 | Stop trivializing MD workforce problems. |
| Q42226125 | Strategies to manage hepatitis C virus (HCV) disease burden. |
| Q42997258 | Stronger hepatitis C virus-specific CD8+ T-cell responses in HIV coinfection |
| Q50723989 | Tacrolimus as intervention in the treatment of hyperlipidemia after liver transplant. |
| Q42986592 | The 1F7 idiotype is selectively expressed on CD5+ B cells and elevated in chronic hepatitis C virus infection |
| Q45353641 | The Annals of Hepatology welcomes the Canadian Association for the Study of the Liver (CASL). |
| Q39213684 | The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm |
| Q37644840 | The use of immunoglobulin therapy for patients undergoing solid organ transplantation: an evidence-based practice guideline. |
| Q50577144 | Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. |
| Q51988034 | Utility of MELD and Child-Turcotte-Pugh scores and the Canadian waitlisting algorithm in predicting short-term survival after liver transplant. |
Search more.